Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors

▤ Summary

Entact Bio appointed John G. Houston, Ph.D., to its Board of Directors. Houston brings deep experience in induced-proximity therapeutics and helped advance the first FDA-approved PROTAC drug while leading Arvinas and holding senior roles at Bristol Myers Squibb and Glaxo Wellcome. Entact says his background will support the company’s Encompass platform and ENTAC pipeline as it works on protein-enhancing medicines. The company positions this appointment as a leadership move that strengthens its push toward new treatments for loss-of-function diseases.

▦ Linked Companies